Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

Vixarelimab showed significant symptom relief and disease progression reduction in prurigo nodularis compared with placebo across all doses. A phase 2b trial found vixarelimab rapidly reduced itch and ...

Nektar Therapeutics is advancing Rezpeg in atopic dermatitis and alopecia areata. Click here for key insights on NKTR's ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

You’ve probably heard of Ozempic, Wegovy, Zepbound, and Mounjaro. But if your algorithm serves up wellness and fitness ...